Biomaterial Database

[Treatment of hyperlipoproteinemia type IIa with a "prudent" diet and clofibrate (author's transl)]. 1978

D P Mertz, and J Suermann

14 previously untreated patients with hyperlipoproteinemia type IIa according to Fredrickson underwent a controlled clinical trial. The study was designed to clarify the effects of clofibrate on the bloodlipids. All patients were willing to cooperate. After leaving their usual dietary habits all of them were given for seven to ten days a "prudent" diet. This diet was rich in vitamins; it had a low caloric-content. 20% of the calories consisted of proteins, 35% of carbohydrates (sweets were omitted) and about 45% of fats with a PS-factor of about 2.2. After the initial dietary treatment all patients were given twice daily for 14 days 500 mg clofibrate. During the use of the "prudent" diet the serum-cholesterol-levels decreased in average with 14.8%. Compared to the values at the beginning of the trial the difference was statistically highly significant. The average-values of triglycerides, phosphatides and the relative percentage of HDL, LDL and VLDL remained unchanged. After the patients received clofibrate there was an additional decrease of the serum-cholesterol-values of 14.8%. The total decrease of the cholesterol-levels compared to the initial values amounted to 27.4%. Furthermore, there was a reduction of the phosphatids in the serum of 14.1% compared to the initial value and of 9.9% compared to the value after dietary treatment alone. Under the combined effects of a "prudent" diet with clofibrate the HDL increased significantly. It can be assumed that clofibrate reduces the serum-cholesterol-levels in cases of hyperlipoproteinemia by decreasing the LDL-fraction, which is rich in cholesterol, and by increasing the HDL-fraction.

UI	MeSH Term	Description	Entries
D006949	Hyperlipidemias	Conditions with excess LIPIDS in the blood.	Hyperlipemia,Hyperlipidemia,Lipemia,Lipidemia,Hyperlipemias,Lipemias,Lipidemias
D008075	Lipoproteins, HDL	A class of lipoproteins of small size (4-13 nm) and dense (greater than 1.063 g/ml) particles. HDL lipoproteins, synthesized in the liver without a lipid core, accumulate cholesterol esters from peripheral tissues and transport them to the liver for re-utilization or elimination from the body (the reverse cholesterol transport). Their major protein component is APOLIPOPROTEIN A-I. HDL also shuttle APOLIPOPROTEINS C and APOLIPOPROTEINS E to and from triglyceride-rich lipoproteins during their catabolism. HDL plasma level has been inversely correlated with the risk of cardiovascular diseases.	High Density Lipoprotein,High-Density Lipoprotein,High-Density Lipoproteins,alpha-Lipoprotein,alpha-Lipoproteins,Heavy Lipoproteins,alpha-1 Lipoprotein,Density Lipoprotein, High,HDL Lipoproteins,High Density Lipoproteins,Lipoprotein, High Density,Lipoprotein, High-Density,Lipoproteins, Heavy,Lipoproteins, High-Density,alpha Lipoprotein,alpha Lipoproteins
D008077	Lipoproteins, LDL	A class of lipoproteins of small size (18-25 nm) and light (1.019-1.063 g/ml) particles with a core composed mainly of CHOLESTEROL ESTERS and smaller amounts of TRIGLYCERIDES. The surface monolayer consists mostly of PHOSPHOLIPIDS, a single copy of APOLIPOPROTEIN B-100, and free cholesterol molecules. The main LDL function is to transport cholesterol and cholesterol esters to extrahepatic tissues.	Low-Density Lipoprotein,Low-Density Lipoproteins,beta-Lipoprotein,beta-Lipoproteins,LDL(1),LDL(2),LDL-1,LDL-2,LDL1,LDL2,Low-Density Lipoprotein 1,Low-Density Lipoprotein 2,LDL Lipoproteins,Lipoprotein, Low-Density,Lipoproteins, Low-Density,Low Density Lipoprotein,Low Density Lipoprotein 1,Low Density Lipoprotein 2,Low Density Lipoproteins,beta Lipoprotein,beta Lipoproteins
D008297	Male		Males
D008875	Middle Aged	An adult aged 45 - 64 years.	Middle Age
D010743	Phospholipids	Lipids containing one or more phosphate groups, particularly those derived from either glycerol (phosphoglycerides see GLYCEROPHOSPHOLIPIDS) or sphingosine (SPHINGOLIPIDS). They are polar lipids that are of great importance for the structure and function of cell membranes and are the most abundant of membrane lipids, although not stored in large amounts in the system.	Phosphatides,Phospholipid
D002149	Energy Intake	Total number of calories taken in daily whether ingested or by parenteral routes.	Caloric Intake,Calorie Intake,Intake, Calorie,Intake, Energy
D002784	Cholesterol	The principal sterol of all higher animals, distributed in body tissues, especially the brain and spinal cord, and in animal fats and oils.	Epicholesterol
D002994	Clofibrate	A fibric acid derivative used in the treatment of HYPERLIPOPROTEINEMIA TYPE III and severe HYPERTRIGLYCERIDEMIA. (From Martindale, The Extra Pharmacopoeia, 30th ed, p986)	Athromidin,Atromid,Atromid S,Clofibric Acid, Ethyl Ester,Ethyl Chlorophenoxyisobutyrate,Miscleron,Miskleron,Chlorophenoxyisobutyrate, Ethyl
D004035	Diet Therapy	Adjusting the quantity and quality of food intake to improve health status of an individual. This term does not include the methods of food intake (NUTRITIONAL SUPPORT).	Diet Therapy, Restrictive,Dietary Modification,Dietary Restriction,Restriction Diet Therapies,Restriction Diet Therapy,Restrictive Diet Therapies,Restrictive Diet Therapy,Diet Modification,Therapy, Diet,Diet Modifications,Diet Therapies,Diet Therapies, Restriction,Diet Therapy, Restriction,Dietary Modifications,Dietary Restrictions,Modification, Diet,Modification, Dietary,Restriction, Dietary,Therapy, Restriction Diet,Therapy, Restrictive Diet